Poller W, Fechner H, Noutsias M, Tschoepe C, Schultheiss H-P
Department of Cardiology and Pneumology, University Hospital Benjamin Franklin, Freie Universität Berlin, Hindenburgdamm 30, 12200 Berlin, Germany.
Z Kardiol. 2002 Dec;91(12):978-91. doi: 10.1007/s00392-002-0862-7.
Coxsackieviruses and adenoviruses are common agents of viral heart disease. In the majority of exposed individuals they do not cause myocardial disease, however, since they are not primarily cardiotropic. Until recently the molecular basis of their anomalous tropism in patients who develop viral heart disease was unknown. An important step towards clarification of the molecular basis of cardiotropic viral infections was achieved in 1997, when a common receptor for the two structurally unrelated viruses was cloned. This coxsackievirus-adenovirus receptor (CAR) is a key determinant for the cellular uptake of both viruses and for the molecular pathogenesis of coxsackievirus and adenovirus diseases. We have mapped the CAR expression in human hearts and observed highly variable expression patterns. Healthy donor hearts had low CAR expression levels, whereas explanted hearts of patients with dilated cardiomyopathy (DCM) displayed high CAR expression in the myocardium. Remarkably, however, heart failure per se was not associated with CAR induction, since in heart failure of non-DCM origin no induction was found. Additional studies on the molecular mechanisms of CAR induction in cardiomyocytes indicated the existence of a cell-cell contact-dependent molecular mechanism regulating CAR expression, whereas cellular virus uptake and low level replication had no effect. Recombinant expression of human CAR in cardiomyocytes strongly increased their virus uptake rate suggesting that CAR induction enhances cardiac vulnerability to viral disease, whereas healthy myocardium is rather resistant to CAR-dependent viruses. Receptor induction may significantly aggravate the clinical course of viral heart disease, so that the blockade of receptor expression or receptor-virus interactions opens new therapeutic perspectives. Elucidation of the molecular mechanism of CAR induction in DCM, but not in heart failure per se, may reveal a particular pathogenetic process in this disease. A broader analysis of the cardiovascular expression patterns of receptors for other potentially cardiotropic viruses (CMV, EBV, HIV, HHV-6, Parvo-B19, etc.) should lead to a better understanding of individual risk factors for viral heart diseases and of their highly variable clinical courses, and offer new therapeutic options.
柯萨奇病毒和腺病毒是病毒性心脏病的常见病原体。然而,在大多数接触这些病毒的个体中,它们不会引发心肌疾病,因为它们并非主要嗜心肌性的。直到最近,它们在罹患病毒性心脏病患者中出现异常嗜性的分子基础仍不为人知。1997年朝着阐明嗜心肌性病毒感染分子基础迈出了重要一步,当时克隆出了这两种结构不相关病毒的共同受体。这种柯萨奇病毒-腺病毒受体(CAR)是这两种病毒细胞摄取以及柯萨奇病毒和腺病毒疾病分子发病机制的关键决定因素。我们已绘制出CAR在人心脏中的表达图谱,并观察到高度可变的表达模式。健康供体心脏的CAR表达水平较低,而扩张型心肌病(DCM)患者的移植心脏心肌中CAR表达较高。然而,值得注意的是,心力衰竭本身与CAR诱导无关,因为在非DCM源性心力衰竭中未发现诱导现象。对心肌细胞中CAR诱导分子机制的进一步研究表明,存在一种调节CAR表达的细胞间接触依赖性分子机制,而细胞对病毒的摄取和低水平复制并无影响。人CAR在心肌细胞中的重组表达显著提高了它们对病毒的摄取率,这表明CAR诱导增强了心脏对病毒性疾病的易感性,而健康心肌对依赖CAR的病毒具有较强抗性。受体诱导可能会显著加重病毒性心脏病的临床病程,因此阻断受体表达或受体-病毒相互作用开辟了新的治疗前景。阐明DCM而非心力衰竭本身中CAR诱导的分子机制,可能会揭示该疾病中一个特定的致病过程。对其他潜在嗜心肌性病毒(巨细胞病毒、EB病毒、人类免疫缺陷病毒、人类疱疹病毒6型、细小病毒B19等)受体的心血管表达模式进行更广泛分析,应能更好地理解病毒性心脏病的个体危险因素及其高度可变的临床病程,并提供新的治疗选择。